Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
Open Access
- 4 March 2024
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 47 (3) , e24248
Abstract
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).Hypothesis: A difference in the cardiovascular efficancy of dapagliflozin versus empagliflozin in DM patients was anticipated, aiming to guide the optimal choice of SGLT2 inhibitors based on cardiovascular outcomes.Methods: From 2014 to 2020, a total of 1549 patients with DM who were prescribed SGLT2 inhibitors such as dapagliflozin or empagliflozin were retrospectively enrolled. We categorized the study population into two groups: dapagliflozin (n = 981) and empagliflozin group (n = 568). The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all‐cause death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HF) over a 3‐year period.Results: Propensity‐score matching was performed (537 patients in each group). The mean age and hemoglobin A1c were 58.2 ± 13.0 years and 8.4 ± 1.7%, respectively. There was no significant difference between the dapagliflozin and empagliflozin groups in the risk of MACE (3.7% vs. 4.8%, hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.73–2.35; p = 0.349). Furthermore, there were no differences between the two groups in secondary endpoints including all‐cause death, MI, stroke, and hospitalization for HF. Prior MI and history of HF were independent predictors of MACE.Conclusions: Dapagliflozin and empagliflozin showed no significant difference of real‐world clinical cardiovascular outcomes in patients with DM over a 3‐year period. Further large randomized clinical trials will be warranted for better evaluation.Keywords
This publication has 25 references indexed in Scilit:
- Fourth Universal Definition of Myocardial Infarction (2018)JACC, 2018
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2018
- The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventionsHeart Failure Reviews, 2018
- Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysisEuropean Journal of Preventive Cardiology, 2018
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsCirculation, 2015
- Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2013
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 DiabetesAnnals of Internal Medicine, 2013
- An Updated Definition of Stroke for the 21st CenturyStroke, 2013
- Glucose Control by the Kidney: An Emerging Target in DiabetesAmerican Journal of Kidney Diseases, 2009